Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Cancer
Launched by HELLENIC COOPERATIVE ONCOLOGY GROUP · Jul 4, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying new ways to understand why some advanced breast cancers respond well to modern treatments while others do not. Researchers are looking at patients with breast cancer that has spread beyond the breast (called metastatic breast cancer) and are focusing on how different types of treatments—such as targeted drugs and immune therapies—work or stop working over time. The goal is to find patterns in the patient’s tumor genetics and other factors that can help doctors predict which treatments will be most effective for each person, so patients get the best care without unnecessary side effects.
Women aged 18 and older with advanced breast cancer, including those with hormone receptor-positive, HER2-positive or low, or triple-negative types, may be eligible to join. Participants will have had at least one cycle of treatment before being included in the study. If you join, you can expect to provide some medical information and biological samples, such as blood or tissue, which will be analyzed using advanced technologies. This helps researchers develop a tool that could guide future treatment decisions. It’s important to know that this study focuses on patients whose cancer has already spread, and participation involves sharing health data and samples to improve understanding of how to fight advanced breast cancer better.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Eligible patients will be 18 years of age and older
- • Histologically confirmed, advanced breast cancer.
- • Diagnosis of i) hormone receptor positive and/or ii) HER2-positive or -low or iii) triple negative breast cancer (TNBC).
- • Patients will be included in the analysis after receiving at least one treatment cycle.
- Exclusion Criteria:
- • Diagnosis of early breast cancer at time of enrollment
- • Unwillingness to provide informed consent
- • Unwillingness to provide biological specimen
- • Lack of comprehensive clinical data
About Hellenic Cooperative Oncology Group
The Hellenic Cooperative Oncology Group (HeCOG) is a prominent clinical trial sponsor based in Greece, dedicated to advancing cancer research and improving patient outcomes through collaborative studies. Comprising a network of oncology professionals, HeCOG focuses on the design, implementation, and management of multicenter clinical trials that evaluate innovative treatment approaches and therapeutic strategies for various cancer types. With a commitment to fostering scientific excellence and enhancing the quality of cancer care, HeCOG actively engages in partnerships with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful execution of its research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Thessaloniki, , Greece
Patients applied
Trial Officials
Elena Fountzilas, MD, PhD
Principal Investigator
Hellenic Cooperative Oncology Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported